Log In
Print
BCIQ
Print
Print this Print this
 

bimagrumab (BYM338)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHuman HuCAL antibody against activin receptor type 2B (ACVR2B)
Molecular Target Activin receptor type 2B (ACVR2B)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today